Henriette Burger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Henriette Burger has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Tonya Marianne Esterhuizen
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
4 shared publications - Alan Barnard
University of Cape Town
3 shared publications - Hayley Irusen
Stellenbosch University, Division of Urology, Cape Town, South Africa
3 shared publications - Liz Gwyther
University of Cape Town
3 shared publications - Rene Krause
University of Cape Town
3 shared publications - Zainab Mohamed
University of Cape Town
3 shared publications
Latest Publications
- 1 December 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (12) , 1378-1383
Brief Report: Prognostic Value of Kaposi Sarcoma Herpes Virus–Associated Clinical Symptom Scores in HIV-Associated Kaposi Sarcoma
Background: Kaposi sarcoma herpes virus (KSHV)-associated inflammatory cytokine syndrome (KICS) is defined by clinical, laboratory, and radiographic findings and KSHV viremia. Whether the presenting clinical symptoms of KICS have prognostic value in patients with HIV-associated Kaposi sarcoma (HIV-KS) initiating therapy is unknown. Setting: Two prospective clinical trials were conducted among participants with mild-to-moderate (A5264/AMC067) and advanced (A5263/AMC066) HIV-KS in low-income and middle-income countries. All participants received antiretroviral therapy, and chemotherapy was given according to the randomly assigned treatment arm. Methods: We developed a Kaposi sarcoma clinical symptom score (KSCS score), derived from the previously described KICS definition to determine whether the score could inform prognosis. The score ranging from 0 to 3 was based on increasing severity of clinical manifestations. We evaluated the impact of baseline KSCS score on progression-free and overall survival using Cox proportional hazard regression. Results: Of 190 participants in A5264/AMC067 and 329 in A5263/AMC066, 150 (78.9%) and 239 (72.6%) had KSCS score ≥1 and 15 (7.9%) and 95 (28.9%) had KSCS score 3, respectively. Independent of the treatment arm, participants with KSCS score 3 had a higher risk of death (A5264/AMC067: adjusted hazard ratio (aHR) = 9.17; 95% CI: 3.60 to 23.41; A5263/AMC066: aHR = 2.99; 95% CI: 1.69 to 5.28) and shorter progression-free survival (A5264/AMC067: aHR = 2.36 95% CI: 1.26 to 4.43; A5263/AMC066: aHR = 2.31; 95% CI: 1.23 to 3.60) compared with those with KSCS score ≤2. Conclusions: KSCS score symptoms are common, especially in advanced HIV-KS. KSCS score 3 is associated with higher risk of progressive KS disease or death, despite treatment with antiretrovirals and chemotherapy. This population may benefit from improved diagnostic and management options.
- 1 December 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (12) , 1378-1383
Brief Report: Prognostic Value of Kaposi Sarcoma Herpes Virus–Associated Clinical Symptom Scores in HIV-Associated Kaposi Sarcoma
Background: Kaposi sarcoma herpes virus (KSHV)-associated inflammatory cytokine syndrome (KICS) is defined by clinical, laboratory, and radiographic findings and KSHV viremia. Whether the presenting clinical symptoms of KICS have prognostic value in patients with HIV-associated Kaposi sarcoma (HIV-KS) initiating therapy is unknown. Setting: Two prospective clinical trials were conducted among participants with mild-to-moderate (A5264/AMC067) and advanced (A5263/AMC066) HIV-KS in low-income and middle-income countries. All participants received antiretroviral therapy, and chemotherapy was given according to the randomly assigned treatment arm. Methods: We developed a Kaposi sarcoma clinical symptom score (KSCS score), derived from the previously described KICS definition to determine whether the score could inform prognosis. The score ranging from 0 to 3 was based on increasing severity of clinical manifestations. We evaluated the impact of baseline KSCS score on progression-free and overall survival using Cox proportional hazard regression. Results: Of 190 participants in A5264/AMC067 and 329 in A5263/AMC066, 150 (78.9%) and 239 (72.6%) had KSCS score ≥1 and 15 (7.9%) and 95 (28.9%) had KSCS score 3, respectively. Independent of the treatment arm, participants with KSCS score 3 had a higher risk of death (A5264/AMC067: adjusted hazard ratio (aHR) = 9.17; 95% CI: 3.60 to 23.41; A5263/AMC066: aHR = 2.99; 95% CI: 1.69 to 5.28) and shorter progression-free survival (A5264/AMC067: aHR = 2.36 95% CI: 1.26 to 4.43; A5263/AMC066: aHR = 2.31; 95% CI: 1.23 to 3.60) compared with those with KSCS score ≤2. Conclusions: KSCS score symptoms are common, especially in advanced HIV-KS. KSCS score 3 is associated with higher risk of progressive KS disease or death, despite treatment with antiretrovirals and chemotherapy. This population may benefit from improved diagnostic and management options.
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500702
Artificial Intelligence–Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant
PURPOSE: Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps that can contribute to treatment delays and interobserver variability. The Radiation Planning Assistant (RPA) is a Web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, artificial intelligence–driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries. MATERIALS AND METHODS: We developed deep learning–based auto-contouring models using nnU-Net and integrated them with knowledge-based planning models trained on curated data sets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. RESULTS: In all, 50 test patients (40 prostate, 10 cervical) were evaluated end-to-end. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. CONCLUSION: We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA's infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500702
Open AccessArtificial Intelligence–Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant
PURPOSE: Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps that can contribute to treatment delays and interobserver variability. The Radiation Planning Assistant (RPA) is a Web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, artificial intelligence–driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries. MATERIALS AND METHODS: We developed deep learning–based auto-contouring models using nnU-Net and integrated them with knowledge-based planning models trained on curated data sets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. RESULTS: In all, 50 test patients (40 prostate, 10 cervical) were evaluated end-to-end. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. CONCLUSION: We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA's infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability.
- Open Access
- 1 January 2026
- Published by AOSIS in African Journal of Primary Health Care & Family Medicine
- Vol. 18 (1) , 5566
Corrigendum: A Delphi study to guide the development of a clinical indicator tool for palliative care in South Africa
- 1 January 2026
- Published by AOSIS in African Journal of Primary Health Care & Family Medicine
- Vol. 18 (1) , 5566
Open AccessCorrigendum: A Delphi study to guide the development of a clinical indicator tool for palliative care in South Africa
- Open Access
- 1 January 2026
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 27 (1) , 7
HIV-associated Kaposi sarcoma: Advanced disease and high mortality of patients referred to a multidisciplinary clinic in South Africa, 2022–2024
Background: Kaposi sarcoma (KS) remains the most common HIV-associated malignancy in South Africa and continues to contribute substantially to the national disease burden, despite the widespread availability of antiretroviral therapy (ART) since 2004. Objectives: To describe the clinical characteristics and outcomes of patients referred to a multidisciplinary HIV-associated KS clinic. Method: A retrospective, descriptive cohort study was conducted at a South African tertiary hospital, including patients diagnosed with HIV-associated KS between January 2022 and December 2024. Data were deidentified, pooled, and analysed using descriptive statistics and univariate analysis. Results: A total of 137 patients were included. Most were on ART at the time of KS diagnosis, with a median CD4 count of 122 cells/µL. Advanced disease was common, with 85% of patients presenting with AIDS Clinical Trial Group (ACTG) poor risk tumour stage KS, including 43% with visceral involvement. The 1-year all-cause mortality rate was 38%, with visceral KS and lower CD4 counts on presentation being significantly associated with increased risk of death. HIV viral suppression was associated with improved survival, while duration of ART prior to KS diagnosis did not significantly affect outcomes. Conclusion: These findings highlight the late stage at presentation and poor prognosis of HIV-associated KS in this cohort, underscoring the urgent need for improved retention in HIV care and earlier diagnosis of KS.
- 1 January 2026
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 27 (1) , 7
Open AccessHIV-associated Kaposi sarcoma: Advanced disease and high mortality of patients referred to a multidisciplinary clinic in South Africa, 2022–2024
Background: Kaposi sarcoma (KS) remains the most common HIV-associated malignancy in South Africa and continues to contribute substantially to the national disease burden, despite the widespread availability of antiretroviral therapy (ART) since 2004. Objectives: To describe the clinical characteristics and outcomes of patients referred to a multidisciplinary HIV-associated KS clinic. Method: A retrospective, descriptive cohort study was conducted at a South African tertiary hospital, including patients diagnosed with HIV-associated KS between January 2022 and December 2024. Data were deidentified, pooled, and analysed using descriptive statistics and univariate analysis. Results: A total of 137 patients were included. Most were on ART at the time of KS diagnosis, with a median CD4 count of 122 cells/µL. Advanced disease was common, with 85% of patients presenting with AIDS Clinical Trial Group (ACTG) poor risk tumour stage KS, including 43% with visceral involvement. The 1-year all-cause mortality rate was 38%, with visceral KS and lower CD4 counts on presentation being significantly associated with increased risk of death. HIV viral suppression was associated with improved survival, while duration of ART prior to KS diagnosis did not significantly affect outcomes. Conclusion: These findings highlight the late stage at presentation and poor prognosis of HIV-associated KS in this cohort, underscoring the urgent need for improved retention in HIV care and earlier diagnosis of KS.
- Open Access
AI-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning with the Radiation Planning Assistant (RPA)
Purpose Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps and clinical hand-offs that contribute to treatment delays and inter-observer variability. The Radiation Planning Assistant (RPA) is a web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, AI-driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries (LMICs). Methods We developed deep learning-based auto-contouring models using nnU-Net and integrated them with knowledge-based planning (KBP) models trained on curated datasets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. Results In total, 50 test patients (40 prostate, 10 cervical) were evaluated. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. Conclusion We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA’s infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability. By reducing reliance on specialist input, this work addresses key barriers to equitable radiotherapy access in resource-limited settings and responds to global calls from the IAEA and WHO to expand radiotherapy capacity. Funding National Institute of Health, National Science Foundation, Rising Tide Foundation, University of Texas MD Anderson Cancer Center
Open AccessAI-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning with the Radiation Planning Assistant (RPA)
Purpose Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps and clinical hand-offs that contribute to treatment delays and inter-observer variability. The Radiation Planning Assistant (RPA) is a web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, AI-driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries (LMICs). Methods We developed deep learning-based auto-contouring models using nnU-Net and integrated them with knowledge-based planning (KBP) models trained on curated datasets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. Results In total, 50 test patients (40 prostate, 10 cervical) were evaluated. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. Conclusion We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA’s infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability. By reducing reliance on specialist input, this work addresses key barriers to equitable radiotherapy access in resource-limited settings and responds to global calls from the IAEA and WHO to expand radiotherapy capacity. Funding National Institute of Health, National Science Foundation, Rising Tide Foundation, University of Texas MD Anderson Cancer Center
- Open Access
- 23 January 2025
- Published by Wiley in Journal of Skin Cancer
- Vol. 2025 (1) , 4779587
Survival Outcomes of a Large Cohort of Acral Melanoma Patients Treated at a South African Referral Hospital
Acral melanoma (AM) is the most common type of melanoma arising in people with skin of color. AM is often diagnosed late and associated with poor outcomes. Melanoma outcomes are also impacted by socioeconomic status. Although uncommon, AM is a public health concern in South Africa because of its epidemiology and association with health access issues, which predispose to late diagnosis. South African patients are managed based on staging systems and treatment guidelines developed for other populations. This cohort study aimed to determine the survival outcomes in a cohort of South African AM patients and how these were associated with demographic, clinical, pathological, and management data. The study included patients diagnosed at a referral hospital between 1 January 2010 and 31 December 2021. Analysis occurred in 2022 and 2023. The main outcomes of interest were survival time in months (overall and progression‐free, OS and PFS). Survival outcomes were analyzed using Kaplan–Meier survival curves. Survival probabilities were compared between subgroups using log‐rank tests. Univariate and multivariable analyses were performed using the Cox proportional hazards models to assess factors associated with survival. Ninety‐one patients were included in the analysis. After a median follow‐up of 28 months (range: 0–151 months), 48 patients (52.7%) had died. The 3‐ and 5‐year survival rates for the entire cohort were 64.8% and 56.0% respectively. Notably, the OS and PFS were not affected by the population group ( p value = 0.628, not significant). The examination of OS and PFS by the clinical stage group demonstrated proportional hazard. Although SLNB comprised a small group, the results appear to be prognostically valid, specifically for OS. The results indicate that the AJCC eighth edition staging is broadly applicable to AM in this population; however, a rigorous comparison was not possible. SLNB appears to be prognostically valid. No difference in survival outcomes by population group was shown.
- 23 January 2025
- Published by Wiley in Journal of Skin Cancer
- Vol. 2025 (1) , 4779587
Open AccessSurvival Outcomes of a Large Cohort of Acral Melanoma Patients Treated at a South African Referral Hospital
Acral melanoma (AM) is the most common type of melanoma arising in people with skin of color. AM is often diagnosed late and associated with poor outcomes. Melanoma outcomes are also impacted by socioeconomic status. Although uncommon, AM is a public health concern in South Africa because of its epidemiology and association with health access issues, which predispose to late diagnosis. South African patients are managed based on staging systems and treatment guidelines developed for other populations. This cohort study aimed to determine the survival outcomes in a cohort of South African AM patients and how these were associated with demographic, clinical, pathological, and management data. The study included patients diagnosed at a referral hospital between 1 January 2010 and 31 December 2021. Analysis occurred in 2022 and 2023. The main outcomes of interest were survival time in months (overall and progression‐free, OS and PFS). Survival outcomes were analyzed using Kaplan–Meier survival curves. Survival probabilities were compared between subgroups using log‐rank tests. Univariate and multivariable analyses were performed using the Cox proportional hazards models to assess factors associated with survival. Ninety‐one patients were included in the analysis. After a median follow‐up of 28 months (range: 0–151 months), 48 patients (52.7%) had died. The 3‐ and 5‐year survival rates for the entire cohort were 64.8% and 56.0% respectively. Notably, the OS and PFS were not affected by the population group ( p value = 0.628, not significant). The examination of OS and PFS by the clinical stage group demonstrated proportional hazard. Although SLNB comprised a small group, the results appear to be prognostically valid, specifically for OS. The results indicate that the AJCC eighth edition staging is broadly applicable to AM in this population; however, a rigorous comparison was not possible. SLNB appears to be prognostically valid. No difference in survival outcomes by population group was shown.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400236
Extension for Community Healthcare Outcomes-Palliative Care in Africa and Quality of Life, Symptoms, Patient Experience, and Caregiver Distress Among Patients With Cancer
PURPOSE: In this study, we aimed to evaluate the association between the Extension for Community Healthcare Outcomes-Palliative Care (ECHO-PC; ECHO Model–Based comprehensive educational and telementoring intervention) for health care professionals (HCPs) and change in patient-reported quality-of-life (QOL; Functional Assessment of Cancer Therapy-General [FACT-G]) among patients with advanced cancer. We also examined the association between ECHO-PC and changes in symptom distress (Edmonton Symptom Assessment Scale [ESAS]), patient experience and satisfaction, and caregiver distress scores. METHODS: ECHO-PC Clinic sessions were conducted twice a month for 1 year by an interdisciplinary team of PC clinicians at the MD Anderson Cancer Center, with participation of experts in PC in sub-Saharan Africa, using standardized curriculum on the basis of PC needs in the region. Study participants included palliative HCPs from ECHO participating programs in Kenya, Nigeria, Ghana, and South Africa. HCPs, their patients, and caregivers were assessed at baseline, 3, 6, 9, and 12 months of the study for QOL (FACT-G), ESAS-Symptom Distress Score (prorated) (SDS), patient experience, satisfaction (FAMCARE-P-16-patient), and caregiver distress (FAMCARE-caregiver). RESULTS: Two hundred seventy patients completed the assessments. Fifty-eight percent was female, the mean age was 56 years, and most common cancer type was breast cancer (24.3%). Multivariate generalized linear mixed model analysis found that ECHO-PC intervention was associated with significant improvement in QOL and symptom distress (FACT-G total score, P = .0433; FACT-G physical well-being, P < .013; FACT-G emotional well-being, P = .0232, and ESAS-SDS, P < .0001). No significant changes were found in patient experience, satisfaction, and caregiver distress scores. CONCLUSION: Our preliminary study found that the ECHO-PC intervention was significantly associated with improvement in patient outcomes including QOL and symptom distress scores. Further studies are needed.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400236
Extension for Community Healthcare Outcomes-Palliative Care in Africa and Quality of Life, Symptoms, Patient Experience, and Caregiver Distress Among Patients With Cancer
PURPOSE: In this study, we aimed to evaluate the association between the Extension for Community Healthcare Outcomes-Palliative Care (ECHO-PC; ECHO Model–Based comprehensive educational and telementoring intervention) for health care professionals (HCPs) and change in patient-reported quality-of-life (QOL; Functional Assessment of Cancer Therapy-General [FACT-G]) among patients with advanced cancer. We also examined the association between ECHO-PC and changes in symptom distress (Edmonton Symptom Assessment Scale [ESAS]), patient experience and satisfaction, and caregiver distress scores. METHODS: ECHO-PC Clinic sessions were conducted twice a month for 1 year by an interdisciplinary team of PC clinicians at the MD Anderson Cancer Center, with participation of experts in PC in sub-Saharan Africa, using standardized curriculum on the basis of PC needs in the region. Study participants included palliative HCPs from ECHO participating programs in Kenya, Nigeria, Ghana, and South Africa. HCPs, their patients, and caregivers were assessed at baseline, 3, 6, 9, and 12 months of the study for QOL (FACT-G), ESAS-Symptom Distress Score (prorated) (SDS), patient experience, satisfaction (FAMCARE-P-16-patient), and caregiver distress (FAMCARE-caregiver). RESULTS: Two hundred seventy patients completed the assessments. Fifty-eight percent was female, the mean age was 56 years, and most common cancer type was breast cancer (24.3%). Multivariate generalized linear mixed model analysis found that ECHO-PC intervention was associated with significant improvement in QOL and symptom distress (FACT-G total score, P = .0433; FACT-G physical well-being, P < .013; FACT-G emotional well-being, P = .0232, and ESAS-SDS, P < .0001). No significant changes were found in patient experience, satisfaction, and caregiver distress scores. CONCLUSION: Our preliminary study found that the ECHO-PC intervention was significantly associated with improvement in patient outcomes including QOL and symptom distress scores. Further studies are needed.
- Open Access
- 29 August 2024
- Published by AOSIS in South African Journal of Oncology
- Vol. 8, 5
Denosumab in irresectable giant cell tumour of the cervical spine
Giant cell tumours of bone (GCTB) are rare benign, locally aggressive bone tumours that are characterised by mononucleated mesenchymal stromal cells that overexpress receptor activator nuclear factor kappa B (RANK) ligand and multinucleated osteoclast-like giant cells that express RANK. Surgery is the primary management option for operable disease but may cause significant functional morbidity in cervical vertebral GCTB. Case series of denosumab use in irresectable GCTB have reported good long term local control and downgrading of surgical extent. Concerns exist about the increased risk of local recurrence when neoadjuvant denosumab is followed by intralesional surgery, and when treatment is discontinued in cases of advanced disease.Contribution: We describe the management of a 21-year-old female with cervical vertebral GCTB with long-term adjuvant denosumab after partial resection who continues to show good clinical and radiologic control.
- 29 August 2024
- Published by AOSIS in South African Journal of Oncology
- Vol. 8, 5
Open AccessDenosumab in irresectable giant cell tumour of the cervical spine
Giant cell tumours of bone (GCTB) are rare benign, locally aggressive bone tumours that are characterised by mononucleated mesenchymal stromal cells that overexpress receptor activator nuclear factor kappa B (RANK) ligand and multinucleated osteoclast-like giant cells that express RANK. Surgery is the primary management option for operable disease but may cause significant functional morbidity in cervical vertebral GCTB. Case series of denosumab use in irresectable GCTB have reported good long term local control and downgrading of surgical extent. Concerns exist about the increased risk of local recurrence when neoadjuvant denosumab is followed by intralesional surgery, and when treatment is discontinued in cases of advanced disease.Contribution: We describe the management of a 21-year-old female with cervical vertebral GCTB with long-term adjuvant denosumab after partial resection who continues to show good clinical and radiologic control.
- Open Access
- 30 July 2024
- Published by AOSIS in South African Journal of Oncology
- Vol. 8, 9
Evaluating a hypofractionated radiotherapy schedule for prostate cancer at an institution in South Africa
The South African Journal of Oncology is a peer-reviewed on-line journal which publishes high quality articles on all aspects of oncology. The Editorial Board strongly supports a multidisciplinary approach to cancer care research as well as translational research in oncology.
- 30 July 2024
- Published by AOSIS in South African Journal of Oncology
- Vol. 8, 9
Open AccessEvaluating a hypofractionated radiotherapy schedule for prostate cancer at an institution in South Africa
The South African Journal of Oncology is a peer-reviewed on-line journal which publishes high quality articles on all aspects of oncology. The Editorial Board strongly supports a multidisciplinary approach to cancer care research as well as translational research in oncology.
- Open Access
- 15 May 2023
- Published by AOSIS in South African Journal of Oncology
- Vol. 7
Erratum: Delays in the referral and primary management of cutaneous malignant melanoma at Tygerberg Hospital
The South African Journal of Oncology is a peer-reviewed on-line journal which publishes high quality articles on all aspects of oncology. The Editorial Board strongly supports a multidisciplinary approach to cancer care research as well as translational research in oncology.
- 15 May 2023
- Published by AOSIS in South African Journal of Oncology
- Vol. 7
Open AccessErratum: Delays in the referral and primary management of cutaneous malignant melanoma at Tygerberg Hospital
The South African Journal of Oncology is a peer-reviewed on-line journal which publishes high quality articles on all aspects of oncology. The Editorial Board strongly supports a multidisciplinary approach to cancer care research as well as translational research in oncology.